SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.

Breast cancer has never had any good serum tumor markers. Therefore, we developed and evaluated a proteomics approach to searching for new biomarkers and building diagnostic models. SELDI-TOF-MS ProteinChip was used to detect the serum protein patterns of 49 breast cancer patients, 51 patients with benign breast diseases, and 33 healthy women. The diagnostic models were developed and validated using bioinformatics tools such as artificial neural networks and discriminant analysis. In total, four models were built and their sensitivities and specificities were satisfactory. The abilities of these models to diagnose stage I breast cancer were not worse than for stages II-IV (P>0.05). Four candidate biomarkers of breast cancer were found. The high sensitivity and specificity achieved by this method show great potential for the early detection of breast cancer and facilitation of discovering new and improved biomarkers.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[3]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[4]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[5]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2004 , 2004, CA: a cancer journal for clinicians.

[6]  M. Snyder,et al.  Protein chip technology. , 2003, Current opinion in chemical biology.

[7]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2006 , 2006, CA: a cancer journal for clinicians.

[8]  M. Hou,et al.  Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. , 1999, The Kaohsiung journal of medical sciences.

[9]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[10]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[11]  P. Hammer,et al.  Ovarian cancer detection by logical analysis of proteomic data , 2004, Proteomics.

[12]  R. Dittadi,et al.  Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer. , 1999, Clinical chemistry.

[13]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[14]  J. Russo,et al.  Biological and molecular basis of human breast cancer. , 1998, Frontiers in bioscience : a journal and virtual library.

[15]  S. Weinberger,et al.  Recent trends in protein biochip technology. , 2000, Pharmacogenomics.